Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.2800
+0.0015 (0.54%)
Apr 28, 2025, 9:40 AM EDT - Market open

Cyclacel Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-11.21-22.56-21.2-18.46-8.45
Upgrade
Depreciation & Amortization
0.010.030.030.040.02
Upgrade
Stock-Based Compensation
0.591.471.511.160.43
Upgrade
Other Operating Activities
-0.04-0.070.040.17-0.09
Upgrade
Change in Accounts Payable
-1.810.32.583.030.03
Upgrade
Change in Other Net Operating Assets
4.474.71-3.78-4.480.12
Upgrade
Operating Cash Flow
-7.99-16.11-20.83-18.54-7.93
Upgrade
Capital Expenditures
--0.01-0.01-0.03-0.1
Upgrade
Investing Cash Flow
--0.01-0.01-0.03-0.1
Upgrade
Issuance of Common Stock
7.821.053.221.9425.99
Upgrade
Preferred Dividends Paid
--0.2-0.2-0.2-0.2
Upgrade
Dividends Paid
--0.2-0.2-0.2-0.2
Upgrade
Other Financing Activities
-----0.06
Upgrade
Financing Cash Flow
7.820.85321.7429.5
Upgrade
Foreign Exchange Rate Adjustments
-0.070.3-0.38-0.020.05
Upgrade
Net Cash Flow
-0.24-14.97-18.213.1521.52
Upgrade
Free Cash Flow
-7.99-16.12-20.83-18.57-8.03
Upgrade
Free Cash Flow Margin
-18581.40%-3837.62%---
Upgrade
Free Cash Flow Per Share
-1.49-18.94-27.77-31.20-33.15
Upgrade
Cash Income Tax Paid
-3.71-4.84-3.31-1.36-1.29
Upgrade
Levered Free Cash Flow
-5.27-11.76-15.34-12.21-6.16
Upgrade
Unlevered Free Cash Flow
-5.27-11.76-15.34-12.21-6.16
Upgrade
Change in Net Working Capital
-1.64-2.65-0.42-0.61-0.14
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q